ライフサイエンスコーパス: MALT

1 MALT has a prominent T-cell signature and a marginal zon

2 MALT lymphomas are characterized genetically by the t(11

3 MALT lymphomas have a more indolent course than non-MALT

4 MALT-1 is expressed broadly in the C. elegans nervous sy

5 evels that resulted in reduced CARMA1/Bcl-10/MALT-1 complex formation and NF-kappaB-dependent cell su

6 , they have similarly analyzed low-grade (12 MALT, 16 CLL/SLL) and high-grade (19 DLCL) lymphomas.

7 . elegans nervous system, and neuronal IL-17-MALT-1 signaling regulates multiple phenotypes, includin

8 anaplastic large cell (Ki-1+) lymphoma, 0/2 MALT lymphoma) showed hypermethylation of the promoter.

9 . pylori-positive chronic gastritis (n = 7), MALT (n = 12), or MALT lymphoma (n = 12) were undertaken

10 ese genes in the MALT, we have established a MALT-specific gene transfer model using replication-defe

11 g the translocation t(1;18)(q21;q21) forms a MALT lymphoma, the growth of which is independent of H.

12 d infiltration and the formation of acquired MALT.

13 cobacter pylori infection, and this acquired MALT may eventually develop into low-grade B-cell MALT l

14 e management of patients with ocular adnexal MALT lymphoma, especially monoclonal antibody therapy an

15 een adequately tested only in ocular adnexal MALT lymphomas where upfront doxycycline may be a reason

16 a state-of-the-art summary of ocular adnexal MALT lymphomas.

17 P. gingivalis seemed to degrade MCPIP-1 and MALT-1 at all tested time points and degradation was inh

18 Gingival keratinocyte MCPIP-1 and MALT-1 mRNA and protein expression responses are regulat

19 MCPIP-1 and MALT-1 protein expression levels were also analyzed immu

20 acteria-induced modifications in MCPIP-1 and MALT-1 responses can be a part of periodontal disease pa

21 The protein levels of MCPIP-1 and MALT-1 were examined by immunoblots and mRNA levels by q

22 . pylori-associated follicular gastritis and MALT lymphomas high endothelial venules coexpressed muco

23 es than both Kraken2/Bracken, KrakenUniq and MALT in all simulations, and fewer than Sigma in simulat

24 that observed in B cells of normal MALT and MALT acquired as a consequence of Helicobacter pylori-as

25 AI was 3.4- and 1.4-fold higher in MALT and MALT lymphoma tissue, respectively, in the same comparis

26 he AI and Cdc2/Cdk1 or cyclin B1 in MALT and MALT lymphoma tissues.

27 cosal venules are similar in normal MALT and MALT lymphomas, and factors controlling normal mucosal B

28 on of the clinical features of nodal MZL and MALT-type MZL showed that more patients with nodal MZL p

29 xpression was suppressed by F. nucleatum and MALT-1 protein expression was suppressed by F. nucleatum

30 ere dramatically increased in the spleen and MALTs.

31 Another MALT lymphoma translocation, t(11;18)(q21;q21), fuses th

32 he LCL and its clonally identical antecedent MALT lymphoma both showed t(11;18).

33 ll these low-grade lesions are classified as MALT lymphomas.

34 than Kraken2/Bracken, KrakenUniq as well as MALT both during database construction and sample analys

35 for apoptotic cells in H. pylori-associated MALT may help in identifying a population of patients wi

36 ar lymphoma (3 cases) and mucosa-associated (MALT) lymphoma (3 cases) strong (2+) pRB staining was li

37 on through interaction with the CARMA1/Bcl10/MALT signaling complex in BCR microdomains.

38 s have been based on the distinction between MALT and non-MALT lymphomas.

39 niques have aided in the distinction between MALT lymphoma and other lymphoproliferative disorders an

40 is work establishes a molecular link between MALT lymphoma and ABC-DLBCL, and provides mouse models t

41 Members of this "Bis-MALT-C(18-28)" series were poor solubilizers of DAGK in

42 on yielded an identical sized band from both MALT and follicular lymphoma.

43 d from colonization of lymphoid follicles by MALT lymphoma cells, following which the tumor cells wer

44 and protein fold in comparison to caspases, MALT-1 proteins (mucosa-associated lymphoidtissue lympho

45 may eventually develop into low-grade B-cell MALT lymphoma.

46 gastritis and other low-grade gastric B-cell MALT lymphomas.

47 In conclusion, MALT subgroups with distinct pathologic features defined

48 alternative to radiotherapy for conjunctival MALT lymphomas.

49 t (MALT1(-/-)) and MALT1 protease-deficient (MALT(PD/PD)) mice to wild-type cells.

50 atients with an increased risk of developing MALT lymphoma.

51 detected CagA expression in 20 of 42 DLBCL (MALT) cases (47.6%) and in 13 of 21 "pure" DLBCL cases (

52 nce interval, 2.8%-7.5%; P = .024) for DLBCL(MALT).

53 o) DLBCL patients and 56.3% (18/32) of DLBCL(MALT) patients achieved complete pathologic remission (p

54 LBCL patients and 94.1% (32/34) of the DLBCL(MALT) patients.

55 ransformed gastric MALT lymphomas, the DLBCL(MALT).

56 Similar to DLBCL(MALT), a substantial portion of early-stage HP-positive

57 ith mucosa-associated lymphoid tissue (DLBCL[MALT]) and without ("pure" DLBCL) the features of MALT l

58 C. elegans MALT-1 forms a complex with homologs of Act1 and IRAK an

59 r it is clinically different from extranodal MALT-type lymphoma, we compared the clinical features of

60 SF15; soluble TNFSF15 then led to TRADD/FADD/MALT-1- and caspase-8-mediated autocrine IL-1 secretion.

61 For MALT lymphomas, local control, disease-free survival, an

62 The majority of data were available for MALT lymphoma of the ocular adnexa (OAML) including a to

63 Studies on the use of doxycycline for MALT lymphomas (137 patients) reported complete response

64 LT lymphoma was 2.5-fold lower than that for MALT tissues.

65 Frequent use of V1-69 appears to differ from MALT lymphomas that develop at other sites.

66 Gastric MALT lymphoma is a model malignancy for examination of h

67 nce imaging (MRI) examinations of 26 gastric MALT lymphoma patients, and 20 [68Ga]Pentixafor-PET/MRI

68 bacter pylori-positive gastritis and gastric MALT lymphoma.

69 depth of infiltration of the wall by gastric MALT lymphoma as measured by endoscopic ultrasound has b

70 with antibiotics can be followed by gastric MALT lymphoma regression in most cases.

71 Apart from gastric MALT lymphoma, antibiotic therapies have been adequately

72 Early-stage, low-grade gastric MALT lymphoma that was associated with Helicobacter pylo

73 Among low-grade gastric MALT lymphoma, mutations were found in 3 of 11 tumors th

74 ecutive patients with stage I to IIE gastric MALT lymphoma who obtained a pathologic remission after

75 In gastric MALT lymphoma Helicobacter pylori is the most common sti

76 elapsed Helicobacter pylori-negative gastric MALT lymphoma, with stage I-IV disease.

77 The pathogenesis of gastric MALT lymphoma has been elucidated to a large degree in r

78 study pathogenesis and treatment of gastric MALT lymphoma in humans.

79 a higher than expected incidence of gastric MALT lymphoma in immunosuppressed transplant recipients

80 have furthered the understanding of gastric MALT lymphoma pathogenesis, clinical behavior, and treat

81 ic marginal zone in a single case of gastric MALT lymphoma.

82 phoepithelial lesions, a hallmark of gastric MALT lymphoma.

83 is associated with HP dependence of gastric MALT lymphoma.

84 t(11;18)(q21,q21) is found in 30% of gastric MALT lymphomas and is associated with a failure to respo

85 A subset of H. pylori-positive gastric MALT lymphomas, including infiltrative tumors, may respo

86 ixafor-PET for detection of residual gastric MALT lymphoma at follow-up were 97.0%, 95.0%, 100.0%, 10

87 sing test for assessment of residual gastric MALT lymphomas after H pylori eradication.

88 t endoscopy demonstrated early-stage gastric MALT lymphoma with associated Helicobacter pylori gastri

89 s efficacy on high-grade transformed gastric MALT lymphomas, the DLBCL(MALT).

90 nvolvement of the marginal zone when gastric MALT lymphomas disseminate to the spleen, which is in ke

91 s for the treatment of patients with gastric MALT lymphoma requiring further treatment beyond H pylor

92 medical records of six patients with gastric MALT lymphoma were retrospectively reviewed.

93 our liver transplant recipients with gastric MALT lymphoma were reviewed.

94 clinical management of patients with gastric MALT lymphoma.

95 ntibacterial therapy in patients with non-GI MALT lymphomas was performed.

96 the time being in patients with other non-GI MALT lymphomas.

97 otic therapy in nongastrointestinal (non-GI) MALT lymphomas.

98 specifically associated with salivary gland MALT lymphoma (SG-MALT-lymphoma).

99 tion signature to that of the salivary gland MALT lymphoma.

100 be involved in the growth of salivary gland MALT lymphomas is further suggested by the noted restric

101 ier work in establishing that salivary gland MALT lymphomas represent a highly selected B-cell popula

102 (VH and VL) expressed by five salivary gland MALT lymphomas were cloned and sequenced.

103 High-grade MALT lymphoma tended to show a slightly higher mutation

104 latter patient was found to have high-grade MALT lymphoma with low-grade MALT lymphoma abutting the

105 gh-grade lesions with or without a low-grade MALT component.

106 have high-grade MALT lymphoma with low-grade MALT lymphoma abutting the tumor.

107 When low-grade MALT lymphoma is suspected on the basis of barium study

108 varying size in four patients with low-grade MALT lymphoma.

109 For low-grade MALT lymphomas confined to the gastric wall and without

110 As many as 50% of low-grade MALT lymphomas contain an (11;18)(q21; q21) chromosomal

111 come in the management of gastric, low-grade MALT lymphomas.

112 nt role in the clonal expansion of low-grade MALT lymphomas.

113 ation frequency (2 of 25, 8%) than low-grade MALT tumor (6 of 95, 6.3%).

114 igh-grade lesions may arise from a low grade-MALT component or arise de novo and can spread to lymph

115 356 pSS patients, of whom 75 had MALT and 19 non-MALT NHL and 600 healthy controls were g

116 Seventy-three were classified as having MALT-type MZL because of involvement of a mucosal site a

117 , accessible, and effective tool to identify MALT lymphoma patients at risk of poor outcomes.

118 between the AI and Cdc2/Cdk1 or cyclin B1 in MALT and MALT lymphoma tissues.

119 rminal caspase recruitment domain (CARD), in MALT lymphomas due to the recurrent t(1;14)(p22;q32).

120 c signaling and implicate its dysfunction in MALT lymphomas.

121 Homing receptor expression in MALT lymphoma B cells was heterogeneous, however, in lin

122 (q21;q21) translocation occurs frequently in MALT lymphomas and creates a chimeric NF-kappaB-activati

123 while the AI was 3.4- and 1.4-fold higher in MALT and MALT lymphoma tissue, respectively, in the same

124 pe 4 (CXCR4) has been previously observed in MALT lymphoma.

125 -1beta, however, no changes were observed in MALT-1 mRNA levels.

126 cosal B-cell traffic are also operational in MALT lymphomas.

127 anscripts were specifically overexpressed in MALT, and 2 of these, MMP7 and SIGLEC6, were validated a

128 orambucil Plus Rituximab Versus Rituximab in MALT Lymphoma) was launched to compare chlorambucil alon

129 mitantly, the BCL10 protein is stabilized in MALT lymphomas harboring this fusion.

130 also revealed distinct molecular subsets in MALT.

131 , both proteins are translocation targets in MALT lymphoma.

132 recurrent t(11;18)(q21;q21) translocation in MALT lymphoma.

133 H pylori-independent MALT develops either in the absence of the bacteria or p

134 ALT-lymphoma International Prognostic Index (MALT-IPI) also significantly discriminated between patie

135 The prognostic index (MALT-IPI) constructed using these 3 parameters identifie

136 The new index, MALT-IPI, is a simple, accessible, and effective tool to

137 the mechanisms underlying API2-MALT1-induced MALT lymphomagenesis are not fully understood.

138 show that concurrent gastric and intestinal MALT lymphomas are derived from the same clone and sugge

139 x cases of concurrent gastric and intestinal MALT lymphomas by polymerase chain reaction (PCR) amplif

140 clones of concurrent gastric and intestinal MALT lymphomas.

141 mucosa-associated lymphoid tissue lymphoma (MALT).

142 ibly an evolutionary forerunner of mammalian MALTs right at the border to the external environment, t

143 were maltreated as infants by their mothers (MALT), had previously self-administered cocaine under a

144 lymphoma (FL), marginal zone lymphoma (MZL), MALT lymphoma or B-small lymphocytic lymphoma (B-SLL) ce

145 ll clone, whereas 15 of 25 t(11;18)-negative MALT lymphomas (60%) showed trisomy of chromosomes 18 (n

146 pSS patients, of whom 75 had MALT and 19 non-MALT NHL and 600 healthy controls were genotyped for the

147 ased on the distinction between MALT and non-MALT lymphomas.

148 The results of treatment of non-MALT lymphomas using radiotherapy also were good, but th

149 tiple histologic subtypes of lymphoma or non-MALT lymphomas (988 patients) reported local control rat

150 of the c. 1298A > C C allele in the pSS non-MALT group compared to controls and patients without NHL

151 MTHFR variants may be involved in SS non-MALT NHL development, through contribution to defective

152 mphomas have a more indolent course than non-MALT lymphomas, and in the conjunctiva a more conservati

153 In normal stomach and normal MALT, alpha 4 beta 7 and CD62L expression reflected the

154 ins by mucosal venules are similar in normal MALT and MALT lymphomas, and factors controlling normal

155 In normal MALT, H. pylori-associated follicular gastritis and MALT

156 ings with that observed in B cells of normal MALT and MALT acquired as a consequence of Helicobacter

157 O-MALT became progressively organized during vertebrate ev

158 kely not a universal mechanism to maintain O-MALT structures in adulthood of teleost fish, sarcoptery

159 ry lymphoid organs include organized MALT (O-MALT) such as the tonsils and Peyer patches.

160 ntial for the formation and maintenance of O-MALT and other secondary and tertiary lymphoid structure

161 These results provide a new view of O-MALT evolution in vertebrates and indicate that differen

162 ranscriptomics suggest that maintenance of O-MALT in nonmammalian vertebrates relies on expression of

163 y shows for the first time the presence of O-MALT in the mucosa of the African lungfish, an extant re

164 gs collectively suggest that the origin of O-MALT predates the emergence of tetrapods and that TNF fa

165 Yet, the molecular drivers of O-MALT structures found in ectotherms and birds remain ess

166 cosa of anuran amphibians, suggesting that O-MALT evolved from amphibian LAs approximately 250 millio

167 ure of mammalian Peyer patches but not the O-MALT of birds or ectotherms.

168 anized secondary mucosal lymphoid tissues (O-MALT) such as Peyer's patches, tonsils, and adenoids.

169 obtained by merging 3 independent cohorts of MALT lymphoma patients.

170 zone B cells are the normal counterparts of MALT lymphoma cells.

171 have been associated with the development of MALT lymphoma including t(11;18) and alterations in Bcl-

172 pathogenetic pathways in the development of MALT lymphomas.

173 ithin chromosome 18 DNA in three examples of MALT lymphoma bearing this translocation.

174 iological, and molecular genetic features of MALT lymphoma.

175 ) and without ("pure" DLBCL) the features of MALT lymphomas, can achieve long-term complete remission

176 on to the IGH locus can promote formation of MALT lymphomas.

177 his truly represented preferential homing of MALT lymphoma to the splenic marginal zone, we have now

178 On the other hand, the AI index of MALT lymphoma was 2.5-fold lower than that for MALT tiss

179 own to be also used in rearranged Ig loci of MALT B cell lymphomas.

180 have been implicated in the pathogenesis of MALT lymphoma.

181 of-function mechanism in the pathogenesis of MALT lymphoma.

182 The local control rate of MALT lymphomas with treatments involving radiotherapy av

183 not as favorable as the treatment results of MALT lymphomas.

184 ease entity rather than an advanced stage of MALT-type MZL because the clinical presentations and sur

185 truly a disease or just an advanced stage of MALT-type MZL.

186 he LCL had trisomy 12, and a small subset of MALT lymphoma cells had trisomy 3 and/or 12.

187 molecular features partly resembled that of MALT B cell lymphoma Ig genes, suggestive of a mechanism

188 ed tumor onset and induced transformation of MALT lymphoma to activated B-cell diffuse large-cell lym

189 compared to the mantle and marginal zones of MALT tissues.

190 can occur, and in studies reporting only on MALT lymphomas (884 patients), the 5-year and 10-year di

191 chronic gastritis (n = 7), MALT (n = 12), or MALT lymphoma (n = 12) were undertaken.

192 ctivity of glycogen synthase kinase 3beta or MALT-1, both of which have been previously shown to medi

193 chronic gastritis tissue, those with MALT or MALT lymphoma had an increase in PCNA labeling index of

194 Secondary lymphoid organs include organized MALT (O-MALT) such as the tonsils and Peyer patches.

195 Only one other MALT lymphoma with t(11;18) showed aneuploidy (trisomy 3

196 ) and DLCLs (12 of 19) showed a loss of p27; MALT and CLL/SLL, however, were p27 positive.

197 The paracaspase MALT 1 is a major player in lymphocyte activation and pr

198 We identify the paracaspase MALT-1 as a critical output of the pathway.

199 BCL10 cDNAs from t(1;14)-positive MALT tumours contained a variety of mutations, most resu

200 API2-MALT1-positive MALT lymphomas manifest antibiotic resistance and aggres

201 11 of 12 polymerase chain reaction-positive MALT lymphomas (92%).

202 Importantly, primary MALT lymphomas harbouring the API2-MALT1 fusion uniquely

203 phoid tissue lymphoma translocation protein (MALT)-1 in human gingival keratinocyte monolayers and or

204 s in early MESA-associated lesions represent MALT lymphomas or more benign types of expansions has be

205 Thirty-seven MALT lymphomas (all previously evaluated for t(11;18) by

206 ciated with salivary gland MALT lymphoma (SG-MALT-lymphoma).

207 on potentially bridges LELs to genesis of SG-MALT-lymphoma.

208 why GPR34 genetic changes associate with SG-MALT-lymphoma and how these mutations contribute to the

209 nd 8 hub genes for distinguishing primary SS/MALT lymphoma from primary SS.

210 ts with primary SS and those with primary SS/MALT lymphoma revealed pathways and molecular targets as

211 modules related to primary SS and primary SS/MALT lymphoma were significantly enriched with genes kno

212 ts with primary SS, patients with primary SS/MALT lymphoma, and subjects without primary SS (non-prim

213 rin-mediated cell adhesion, while primary SS/MALT lymphoma-associated modules were enriched with gene

214 ular mechanisms of primary SS and primary SS/MALT lymphoma.

215 Although early life stress (MALT) did not significantly impact measures of cocaine's

216 The MALT-lymphoma International Prognostic Index (MALT-IPI)

217 oma occurred 6 months after excision and the MALT lymphoma remained indolent during the course of her

218 howed the same sized dominant product in the MALT lymphoma and the follicular lymphoma.

219 In the MALT lymphoma group, time-matched gastric biopsies were

220 To study the roles of these genes in the MALT, we have established a MALT-specific gene transfer

221 ith extranodal marginal-zone lymphoma of the MALT.

222 cell development, these findings suggest the MALT lymphoma cell of origin may be a germinal center B

223 his review we provide an introduction to the MALT, highlight barriers to vaccine delivery at differen

224 rising in mucosa-associated lymphoid tissue (MALT) are indolent B-cell tumors that have a predilectio

225 as of the mucosa-associated lymphoid tissue (MALT) arise from lymphoid populations that are induced b

226 inal zone mucosa-associated lymphoid tissue (MALT) B-cell lymphoma is the most common extranodal non-

227 as of the mucosa-associated lymphoid tissue (MALT) have recently been shown to be associated with Hel

228 defects, mucosa-associated lymphoid tissue (MALT) hyperplasia, and dysplasia.

229 mphoma of mucosa-associated lymphoid tissue (MALT) is related to Helicobacter pylori infection and ma

230 igin) and mucosa-associated lymphoid tissue (MALT) lymphoma (19 of 45 = 42%) (postgerminal center), b

231 f gastric mucosa-associated lymphoid tissue (MALT) lymphoma (GML).

232 pulmonary mucosa-associated lymphoid tissue (MALT) lymphoma (n = 33) and compared the results to GEP

233 r adnexal mucosa-associated lymphoid tissue (MALT) lymphoma (POAML) is the most common orbital tumor,

234 ximab for mucosa-associated lymphoid tissue (MALT) lymphoma and steroids for prolonged cough.

235 r gastric mucosa-associated lymphoid tissue (MALT) lymphoma cells preferentially to localize around r

236 f gastric mucosa-associated lymphoid tissue (MALT) lymphoma currently relies on esophagogastroduodeno

237 iption of mucosa-associated lymphoid tissue (MALT) lymphoma in 1983 rapid advances have been made in

238 low-grade mucosa-associated lymphoid tissue (MALT) lymphoma in the parotid gland.

239 1;q21) in mucosa-associated lymphoid tissue (MALT) lymphoma induces proteolytic cleavage of NF-kappaB

240 f gastric mucosa-associated lymphoid tissue (MALT) lymphoma is dependent on Helicobacter pylori infec

241 Gastric mucosa-associated lymphoid tissue (MALT) lymphoma is indolent and often associated with Hel

242 Mucosa-associated lymphoid tissue (MALT) lymphoma is the most common extranodal lymphoid ce

243 Mucosa-associated lymphoid tissue (MALT) lymphoma is the most common extranodal lymphoid ne

244 g gastric mucosa-associated lymphoid tissue (MALT) lymphoma linked with Helicobacter pylori infection

245 Mucosa-associated lymphoid tissue (MALT) lymphoma of the stomach (MLS) has recently been de

246 ry showed mucosa-associated lymphoid tissue (MALT) lymphoma with immunoglobulin kappa monotype.

247 disease, mucosa-associated lymphoid tissue (MALT) lymphoma, and gastric adenocarcinoma.

248 disease, mucosa-associated lymphoid tissue (MALT) lymphoma, as well as hyperplastic polyps, hyperpla

249 h gastric mucosa-associated lymphoid tissue (MALT) lymphoma, much less is known about the value of an

250 h gastric mucosa-associated lymphoid tissue (MALT) lymphoma, treatment-related toxicity should be min

251 gastric mucosae-associated lymphoid tissue (MALT) lymphoma.

252 cation of mucosa-associated lymphoid tissue (MALT) lymphoma.

253 2;q32) of mucosa-associated lymphoid tissue (MALT) lymphoma.

254 cation in mucosa-associated lymphoid tissue (MALT) lymphoma.

255 cation in mucosa-associated lymphoid tissue (MALT) lymphoma.

256 lmarks of mucosa-associated lymphoid tissue (MALT) lymphoma.

257 ents with mucosa-associated lymphoid tissue (MALT) lymphomas (HR = 0.26, 95%CI: 0.11-0.59, p = 0.001)

258 enesis of mucosa-associated lymphoid tissue (MALT) lymphomas is associated with independent chromosom

259 Mucosa-associated lymphoid tissue (MALT) lymphomas most frequently involve the gastrointest

260 20 (6.7%) mucosa-associated lymphoid tissue (MALT) lymphomas, 4 of 42 (9.5%) follicular lymphomas, an

261 gy of the mucosa-associated lymphoid tissue (MALT) lymphomas, has been implicated in inflammatory pro

262 s in some mucosa-associated lymphoid tissue (MALT) lymphomas.

263 ations in mucosa-associated lymphoid tissue (MALT) lymphomas.

264 Mucosa-associated lymphoid tissue (MALT) may accumulate within gastric mucosa as a result o

265 phomas of mucosa-associated lymphoid tissue (MALT) origin, ranging from further evidence of the role

266 rise from mucosa-associated lymphoid tissue (MALT) secondary to chronic Helicobacter pylori (H. pylor

267 with the mucosa-associated lymphoid tissue (MALT) to induce both mucosal and systemic immunity.

268 (MZL) of mucosa-associated lymphoid tissue (MALT) type is listed as a distinctive entity.

269 ary gland mucosa associated lymphoid tissue (MALT) type lymphomas are B-cell neoplasms that develop o

270 ary gland mucosa-associated lymphoid tissue (MALT) type lymphomas are typically indolent B-cell neopl

271 mphoma of mucosa-associated lymphoid tissue (MALT) type.

272 mphoma of mucosa-associated lymphoid tissue (MALT) with a secondary intestinal spread.

273 phomas of mucosa-associated lymphoid tissue (MALT), the clonal relationship between the two tumors an

274 atures of mucosa-associated lymphoid tissue (MALT), the pure (de novo) DLBCLs, in comparison with its

275 n orbital mucosa-associated lymphoid tissue (MALT)-type B cell lymphoma.

276 shed that mucosa-associated lymphoid tissue (MALT)-type lymphomas may develop from MESA, the issue of

277 ithin the mucosa-associated lymphoid tissue (MALT).

278 mphoma of mucosa-associated lymphoid tissue (MALT).

279 mphoma of mucosa-associated lymphoid tissue (MALT).

280 ma of the mucosa-associated lymphoid tissue (MALT).

281 ) in the mucosal-associated lymphoid tissue (MALT).

282 in the mucosal-associated lymphoid tissues (MALTs).

283 apoptosis may confer a survival advantage to MALT B-cells, and constitutive NF-kappaB activation may

284 ar evolution of pathogen-specific B cells to MALT B cell lymphoma occurs.

285 the transformation of H. pylori gastritis to MALT lymphoma, the extent of cell proliferation, cell vi

286 olution of H. pylori-associated gastritis to MALT lymphoma.

287 ge cell lymphoma (LCL) arising subsequent to MALT lymphoma, and 16 controls were tested by FISH using

288 d gag genes followed by an intranodal tonsil MALT boost with MVA encoding the same genes protects fro

289 ombination of systemic and intranodal tonsil MALT vaccination could induce robust adaptive and innate

290 y expressed at high levels in all four trout MALT.

291 ly in aggressive and antibiotic unresponsive MALT lymphomas, and may further implicate the biologic i

292 ces were trimmed for quality, analyzed using MALT, MEGAN, and alignment scripts, and integrated with

293 patients initially diagnosed elsewhere with MALT lymphoma.

294 on to systemic disease seems high, even with MALT lymphomas, and treatment with radiation is still re

295 lize and optimize treatment of patients with MALT lymphoma.

296 al MZL was lower than that for patients with MALT-type MZL (56% v 81%; P =.09), with a similar result

297 ared to chronic gastritis tissue, those with MALT or MALT lymphoma had an increase in PCNA labeling i

298 d a large mass (> or = 5 cm) than those with MALT-type MZL (31% v 68%; P =.03).

299 l (30% v 75%; P =.007) rates than those with MALT-type MZL.

300 nopathy (56% v 14%; P <.001) than those with MALT-type MZL.